Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
---|---|---|---|---|---|---|---|
Jul 17, 2020 | SVP/GM, Vascular Access | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 262 | $9.46 | 24,566 | |
Jul 17, 2020 | Director, President and CEO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 2,131 | $9.46 | 308,477 | |
Jul 17, 2020 | SVP Global Operations and R&D | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 254 | $9.46 | 23,708 | |
Jul 17, 2020 | EVP and CFO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 354 | $9.46 | 60,266 | |
Jul 14, 2020 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 15,323 | -- | 36,663 | |
Jul 14, 2020 | SVP/GM, Vascular Access | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 6,726 | -- | 24,828 | |
Jul 14, 2020 | SVP/GM, Vascular Access | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 13,453 | -- | 13,453 | |
Jul 14, 2020 | SVP/GM, Vascular Access | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 19,800 | -- | 19,800 | |
Jul 14, 2020 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 54,435 | -- | 310,608 | |
Jul 14, 2020 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 108,871 | -- | 108,871 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.